GSA Capital Partners’s Novartis NVS Stock Holding History

GSA Capital Partners’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$433K	Buy	+2,762	New	+$414K	0.03%	1088
2017 Q3	–	Sell	-5,670	Closed	-$424K	–	1810
2017 Q2	$424K	Buy	+5,670	New	+$402K	0.03%	1086
2016 Q2	–	Sell	-3,552	Closed	-$231K	–	1856
2016 Q1	$231K	Buy	+3,552	New	+$242K	0.01%	1432

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

GSA Capital Partners's NVS Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Novartis (NVS) in Q2 2026: 2,762 shares worth $433K. The stake represents 0.03% of the portfolio and ranks #1088 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in NVS as recently as Q2 2017.

GSA Capital Partners first reported a position in NVS in Q1 2016 and has held it in 3 quarters since. 1,625 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

GSA Capital Partners held 2,762 shares of Novartis worth $433K as of Q2 2026.
Novartis was a new GSA Capital Partners position in Q2 2026.
Novartis made up 0.03% of GSA Capital Partners's portfolio in Q2 2026, its #1088 holding.
GSA Capital Partners first reported a position in Novartis in Q1 2016 and has held it in 3 quarters since.
1,625 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.